Annemans L, Vanoverbeke N, Tecco J, D'Hooghe D
Vrije Universiteit Brussel, Brussels, Belgium.
Eur Addict Res. 2000 Jun;6(2):71-8. doi: 10.1159/000019013.
We compared the costs of acamprosate in maintaining abstinence in weaned alcoholic patients, to no pharmaceutical treatment over a 24-month period. A controlled trial (n=448) involving a 12-month treatment with acamprosate and a 12-month follow-up showed a significant advantage of acamprosate over placebo in the prevention of relapse. For the economic analysis, the average costs of relapses from the health insurance perspective were calculated based on a Belgian survey among general practitioners and on an observational prospective Belgian trial among specialists. Calculations resulted in net cost savings of 21,301 BEF (528 Euro) per patient over a 24-month period for acamprosate compared to no pharmaceutical treatment, explained by fewer acute hospitalisations for detoxification and less institutionalised rehabilitation. A global anticipated net saving of 70 million BEF (1.74 million Euro) over 2 years was estimated for the Belgian health insurance.
我们比较了在24个月期间，阿坎酸在维持戒酒的酒精依赖患者戒断状态方面的成本与不进行药物治疗的成本。一项对照试验（n = 448），包括12个月的阿坎酸治疗期和12个月的随访期，结果显示在预防复发方面，阿坎酸比安慰剂具有显著优势。对于经济分析，从医疗保险角度计算复发的平均成本，是基于对比利时全科医生的一项调查以及对比利时专科医生的一项前瞻性观察性试验。计算结果表明，与不进行药物治疗相比，在24个月期间，使用阿坎酸治疗每位患者可节省净成本21,301比利时法郎（528欧元），这是由于解毒的急性住院次数减少以及机构康复次数减少所致。据估计，比利时医疗保险在两年内预计可节省总计7000万比利时法郎（174万欧元）的净成本。
